
update in pathogenesis of vascular calcification

ELHAM RAMEZANZADEH Assistant Professor of Nephrology GUMS



- Overview
- Mechanism of vascular calcification
- Factors involved in vascular calcification.
- Calcification inhibitors
- Therapeutic potentials
- Conclusions

Overview





Cardiovascular disease is the most common cause of death in patients with CKD and

vascular calcification is one of the strongest predictors of cardiovascular risk.

Vascular calcification is common in patients with CKD and ESRD,

in whom it correlates with both lower <u>eGFR and</u> <u>CKD-MBD</u>.







Overview



VC can be present at different layers of the arterial wall (intima, media, or both).











- In contrast to the predominant intimal calcification observed in the absence of kidney disease,
- the pattern of vascular calcification in patients with advanced CKD includes both intimal and medial calcification.

 Of note, the severity and progression of vascular calcification is generally much more marked in patients with CKD than in people of comparable age, gender, and ethnicity in the general population.




Microcalcification or spotty calcification present in atheromatous plaques, though <u>very difficult</u> to <u>detect</u> using regular radiological techniques, may <u>negatively</u> <u>impact plaque stability.</u>

This clearly is a very different process compared to the <u>large longitudinal confluent</u> regions of arterial wall calcification typically seen in stage 5 CKD.

Calcification of the tunica media



Arterial medial calcification <u>is not just the</u> result of the simple passive process of calcium deposition <u>but an active process</u> in response to pathological conditions, including Aging, inflammation, diabetes, CKD, and phenotypic switch of resident cells.



<u>Several risk factors</u> may induce accelera vascular aging ;




"classic";

calendar age, gender, CKD and dialysis vintage, inflammatory status, disorders of calcium phosphate, and diabetes, and

"<u>non-classic"</u>;


as abnormal levels of bone-related proteins:


fetuin-A, MGP, pyrophosphate, osteoprotegerin, and BMP-2.



The prevalence and progression of VC increases rapidly once patients are on dialysis and


the phenotype of vessels of younger dialysis patients is comparable with that of octogenarians without CKD.





The pathogenesis of especially P-induced VC indeed that high P concentration in growth media causes VC through specific activation of the core-binding factor alpha-1, an osteoblast-specific gene, that regulates the expression of several bone morphogenic proteins.

• Clearly, all these data indicate that VC is an active pathobiological process.








 the mechanism behind how phosphorus results in apoptosis is uncertain, but may be due to interruptions in normal mitochondrial energy metabolisms of VSMC is a key regulator of VSMC calcification.


Apoptosis in VSMC occurs before the onset of calcification .

- Matrix vesicles, produced by budding from chondrocytes and osteoblasts, appear to play a role in apoptosis induced vascular calcification .
- The matrix vesicles originated from VSMC may be fragments of apoptotic cells.
- These matrix vesicles/apoptotic bodies possess the capacity to concentrate and crystallize calcium as they have all of the essential proteins for calcification.










fetuin-A;

a hepatocyte-derived glycoprotein,

Fetuin-A is an <u>extracellular calcium-regulatory protein</u> acting as a strong inhibitor of Ca-P deposition.

Fetuin-A is one of the most abundant proteins in bone, accounting for <u>25% of noncollagenous</u> proteins,

primary CPP secondary CPPs,





fetuin-A has antiapoptotic activity in VSMC.

Fetuin-A is responsible for mineral accumulation in bone from plasma.


Specifically, fetuin-A binds calcium phosphate and calcium carbonate with high affinity.

In CKD fetuin-A declines.


Hemodialysis patients with lower serum fetuin-A levels have a major risk of cardiovascular (CV) and all-cause mortality.


- Klotho deficiency


- FGF23




Klotho Deficiency in CKD









Nefrologia (English Version). 2016;36:368-75





Extracellular MGP;

matrix-carboxyglutamic acid protein (Matrix-Gla protein, MGP)











The second prominent feature in the medial layer of CKD patients is local inflammation.

Importantly, it is **possible that the previously mentioned cellular changes** are induced by inflammation,


while the opposite may occur as well: inflammation induced by micro-calcification.



Calcification of the tunica intima

Calcification in association with atherosclerosis is not a new phenomenon.

- There is mounting evidence pointing to a different process than the sequence of events occurring in the medial layer, as described above, driving calcification in atherosclerotic plaques.
- More so than in the medial layer, <u>calcification in the intima</u> appears to be a <u>secondary phenomenon of inflammation</u> but still dependent on infiltrating cells into the early atheromatous lesion.
- Infiltrating cells are mostly VSMC and macrophages.



VSMC-derived BMP2 enhances plaque calcification, exacerbated by factors derived from infiltrating macrophages.

Moreover, these macrophages downregulate MGP, thereby reducing defense against crystallization.

Microcalcification in turn may attract macrophages.

Interestingly, osteochondrogenesis appears to be a *secondary phenomenon of primary inflammatory processes* in the plaque or its surroundings.

In this respect, atherosclerotic plaque calcification fundamentally differs from primary media calcification, in which transdifferentiation of local VSMC appears to be a more proximal event.



Once established, atherosclerosis and calcification alter local mechanical shear stress.

Recent preclinical studies suggest that mechanical sensing influences arterial wall shear stress on the inflammatory signaling pathway.

In fact, both high and low wall shear stress may impact apoptosis_signal regulation, e NOS, inhibitor of NFK B kinase, VCAM 1, and other pathways that play a fundamental role in the pathogenesis_of VC.

Thus, biomechanical forces (i.e., wall shear stress) play an important role in the natural history of coronary atherosclerosis




Table 1 | Properties of atherosclerotic plaques at high risk of rupture

Large and necrotic lipid core Spotty calcification Neovascularization Macrophage and other cellular infiltration Thin fibrous cap

Example of discordant findings using different imaging techniques in a patient with unstable angina.

(a) On the left a multiplanar reconstruction of *multisliced CT* demonstrates noncalcified and mixed plaques.

The middle panels show both grayscale intravascular ultrasound images and the corresponding colored virtual histology intravascular ultrasound images. (b) On location, a small amount of plaque in the proximal right coronary artery is seen, not visible on multisliced CT. Thin cap fibroatheroma with a large amount of necrotic core is detected in (c) proximally and (e) distally located noncalcified plaques of the right coronary artery. (d) A corresponding cross-section of a mixed plaque in the midright coronary artery shows plaque with calcium on virtual histology intravascular ultrasound. (f,g) Multiple obstructive stenoses in the right coronary artery were confirmed on invasive coronary angiography, but the severity of anatomical stenosis does not correspond to the quantity of necrotic core, for instance visible on location c. Virtual histology intravascular ultrasound plaque components: dark green, fibrotic tissue; light green, fibro-fatty tissue; red, necrotic core; white, dense calcium.






Conclusion;

In CKD patients, <u>many different factors</u> are involved in the pathogenesis of VC, which is <u>usually much more pronounced than in people</u> <u>without CKD</u>.




Is it possible to reverse VC in CKD?



Given the undisputed role of some components of <u>mineral balance</u>, <u>the focus</u> has been on these components.

As <u>higher</u> serum concentrations of <u>P</u> are associated with <u>more</u> <u>extensive CAC</u> in CKD patients, Overall, <u>however</u>, <u>clinical studies</u> with <u>various P binder</u> therapies have been rather <u>disappointing</u> in terms of <u>clinical outcomes</u> and <u>found only relatively small differences</u> in the <u>progression of vascular</u> calcification.


In ESRD, the <u>avoidance or limited use of calcium-containing P binders</u> is advocated in part based on a <u>more rapid progression</u> of CAC.



<u>Vitamin D</u> associated with VC in hemodialysis patients (Ushaped relationship).


Vitamin D retains a likely mixture of **procalcific effects**, such as a <u>direct effect on VSMC</u>, promoting VC by <u>raising P and calcium</u>, over-suppression of PTH leading to adynamic bone disease and low bone turnover.

On the contrary, vitamin D may also have **anti-inflammatory and immunomodulatory** effects across the CV system, **inhibit the production of renin and myocyte proliferation**, and prevent or alleviate overt hyperparathyroidism.




Recently, the effects of **calcimimetics** have <u>gained interest</u>. However, **none of these interventions**, although possibly affecting the rate of progression, actually induced **absolute regression** of VC.

- The potential role of sodium thiosulfate, a treatment associated with calciphylaxis, as a chelating agent for clinical arterial calcification deserves additional exploration.
- A final promising development is the supplementation of vitamin K, because its deficiency limits the bioactivity of MGP as a calcification inhibitor.



 Intuitively, *kidney transplantation* could be considered the best option to regress VC, but o<u>bservational studies</u> following mainly CAC are generally disappointing in this regard In terms of treatment, several key questions remain.



<u>Although without doubt the amount of calcification is associated with</u> <u>overall atherosclerotic volume</u>, more intense calcifications <u>do not</u> <u>predict future plaque</u> rupture and subsequent arterial occlusion by thrombosis. .

<u>Despite the consistent epidemiological association between the</u> <u>amount and progression of VC</u>, <u>no study has convincingly</u> <u>demonstrated that interventions that modulate the course of VC</u> <u>change patient outcome</u>.



However, given the complex and diverse nature of processes leading to VC,....

Interventions that target several pathological interacting processes ...could be a useful approach for future research.

